Protagonist Therapeutics (PTGX) Leerink Global Healthcare Conference 2026 summary

Strategic outlook and financial position

• Anticipates two FDA approvals for partnered products in 2026, with strong R&D pipeline momentum and surplus cash expected to drive shareholder value decisions in the coming year.

• NDA for oral IL-23 antagonist (partnered with J&J) filed in July 2023, with approval expected in Q3 2024; rusfertide (partnered with Takeda) received priority review, also targeting Q3 2024 approval.

• Opt-in decision for rusfertide partnership expected in Q2 2024, potentially triggering a $400M milestone payment, with $200M upfront.

• Company is fully funding its pipeline and expects to have surplus capital, prompting considerations for shareholder returns.

Pipeline and clinical development updates

• Oral IL-17 (PN-881) in phase I, with a go/no-go decision for phase II expected by Q3 2024 based on PK data; oral hepcidin to enter clinical development by year-end.

• Anti-obesity agents advancing, with sub-Q phase I starting mid-year and oral formulation following; both expected to yield key phase I readouts.

• Oral IL-23 (ICO) is first-in-class, with J&J market research indicating high patient switch potential from injectables and new market creation opportunities.

• Strong phase II data in ulcerative colitis (30% clinical remission) and direct phase III entry for Crohn’s disease.

Commercial and partnership strategy

• Rusfertide partnership with Takeda structured for optionality: opt-out yields 14–29% royalties, with 29% above $1.5B sales; opt-in triggers milestone payments.

• Oral hepcidin is fully owned, with Takeda holding right of first negotiation; focus will be on polycythemia vera, skipping beta thalassemia.

• IL-17 program aims for high potency and specificity, targeting both A and F isoforms, with clinical development initially focused on moderate to severe psoriasis.

• Obesity pipeline includes both sub-Q and oral triple agonists, with the same drug substance for both, enabling flexible treatment strategies.